癌症患者急性呼吸窘迫综合征:YELENNA 前瞻性多国观察性队列研究
该多国前瞻性观察性队列研究纳入欧洲和北美13个国家715例癌症合并ARDS患者,其中73.4%为血液系统恶性肿瘤、26.6%为实体瘤,31.2%接受过造血干细胞移植(168例异基因)。主要终点90天死亡率为73.2%,ICU死亡率55.3%,住院死亡率70.9%。多因素分析显示高龄、外周血管疾病、入组时重度ARDS、急性肾损伤和以限时试验方式收入ICU是全因90天死亡率升高的独立预测因素,淋巴瘤与较低90天死亡率相关。在322例(45.7%)入组时重度ARDS患者中,90天死亡率为82.2%,接受ECMO者(n=58,18%)与未接受者分别为82.6% vs 80.7%(P=0.89),双重校正重叠和倾向加权Cox混合效应模型结果不变(校正HR 1.12,95%CI 0.65-1.94,P=0.69)。作者认为需要就ICU治疗目标进行细致讨论,并对ECMO指南在该人群中的普适性提出担忧。
要点
- 癌症合并ARDS患者90天死亡率为73.2%,ICU死亡率55.3%,住院死亡率70.9%。
- 入组时重度ARDS患者(322例,45.7%)90天死亡率为82.2%。
- 重度ARDS患者中接受ECMO者(n=58,18%)与未接受者90天死亡率分别为82.6% vs 80.7%(P=0.89),校正HR 1.12(95%CI 0.65-1.94,P=0.69)。
- 高龄、外周血管疾病、入组时重度ARDS、急性肾损伤和以限时试验方式收入ICU是90天死亡率升高的独立预测因素;淋巴瘤与较低90天死亡率相关。
- 作者认为需要就ICU治疗目标进行细致讨论,并对ECMO指南在该人群中的普适性提出担忧。
适用人群与场景
- 欧洲和北美13个国家的癌症合并ARDS患者,共715例;73.4%为血液系统恶性肿瘤,26.6%为实体瘤;31.2%接受过造血干细胞移植(168例异基因)。
研究设计与关键结果
- 多国前瞻性观察性队列研究,纳入13个国家715例癌症合并ARDS患者,主要终点为90天死亡率。
- ICU死亡率55.3%,住院死亡率70.9%,90天死亡率73.2%。
- 多因素分析显示高龄、外周血管疾病、入组时重度ARDS、急性肾损伤和以限时试验方式收入ICU(对照为全力救治)是90天死亡率升高的独立预测因素;淋巴瘤与较低90天死亡率相关。
- 入组时重度ARDS患者322例(45.7%),90天死亡率为82.2%;接受ECMO者(n=58,18%)与未接受者90天死亡率分别为82.6% vs 80.7%(P=0.89)。
- 双重校正重叠和倾向加权Cox混合效应模型显示,ECMO与90天死亡率无显著关联(校正HR 1.12,95%CI 0.65-1.94,P=0.69)。
证据类型、等级与局限
- 证据类型:前瞻性多国观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,癌症合并ARDS患者(尤其是重度ARDS)90天死亡率高,无论是否使用ECMO,需要就ICU治疗目标进行细致讨论。
- 作者认为,该研究结果对ECMO指南在该人群中的普适性提出担忧。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS.
METHODS: We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality.
RESULTS: Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (n = 58, 18%) and those who did not (82.6% vs. 80.7%, P = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65-1.94; P = 0.69).
CONCLUSION: Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.
参考来源
- Schellongowski P, Darmon M, Eller P, et al. Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study. Intensive Care Med. 2025. PMID: 40996503. doi:10.1007/s00134-025-08113-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。